SOLUtion Medical

The Opportunity: Adrenal crisis requires immediate cortisol, yet current kits involve 14+ steps that can be difficult for patients and caregivers in emergencies. SOLUtion Medical is developing TwistJECT®, a patented prefilled syringe and autoinjector platform intended to streamline preparation and use.

With 250K at-risk U.S. patients and up to 6.5M globally, the platform is being designed to meet a substantial unmet need and enable expansion into high-value injectable markets.

What began as a founder-driven response to a personal medical challenge has evolved into a scalable platform opportunity within a $1.3T sector. Our technology is being engineered to support improved stability, cost-efficiency, and cold-chain independence—aiming to make complex injectables more accessible.

This represents an impact-driven opportunity with meaningful commercial potential investor returns. Investors include Keiretsu Forum, Golden Seeds, Mass Medical Angels, Osterburg Capital, Helix Fund, Band of Angels, Park City Angels, South Coast Angel Network, NW Angel Fund, Osterburg Capital, and Helix Fund.

SOLUtion projects $145M in U.S. sales, with meaningful ex-US and pipeline expansion upside. Revenue is modeled on net pricing with expected ~85% gross margins across products. Pricing and reimbursement strategy is informed by 1) historical IMS/IQVIA analog data, 2) coverage, coding, and payment assessment, and 3) real-world patient insights. The company anticipates a Tier 3 pathway supportive of broad patient access with no prior authorization or step-through therapy required.

Team